Clinical trials: Psychosis NOS
Early Psychosis
Decision-making and Decision Support Among Emerging Adults With First Episode Psychosis
The purpose of this study is to evaluate the impact of an antipsychotic medication decision aid and interpersonal and cognitive factors, such as attachment style and motivation, on emerging adults' ability to engage in shared…
- Trial name
- NCT04373590
- Testing
- Decision aid
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Temple University
Schizophrenia
Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate Cortex Activation in Schizophrenia
This will be a single site pilot study. 20 subjects with EPP (Early Phase Psychosis), defined as medical record documentation of the onset of clinically significant psychotic symptoms within the past 10 years, will be enrolled.
- Trial name
- rTMS-FPCC (NCT04309370)
- Testing
- 20 Hz rTMS
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Indiana University
Schizophrenia, Schizoaffective Disorder
Interventions to Improve Functional Outcome and Persistent Symptoms in Schizophrenia
Many individuals with schizophrenia continue to hear voices, have false beliefs, and problems with attention, memory planning and everyday functioning even with medication treatment.
- Trial name
- Mcog (NCT01915017)
- Testing
- Cognitive Behavior Therapy for Psychosis, Cognitive Adaptation Training, Multi-modal Cognitive Therapy
- Volunteers
- 178 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Bipolar Disorder
Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder
This study will evaluate the effectiveness of interpersonal and social rhythm therapy (IPSRT) versus clinical status and symptom response therapy (CSSRT) in reinforcing the treatment of bipolar disorder in individuals who are…
- Trial name
- NCT00227968
- Testing
- Interpersonal Social Rhythm Therapy (IPSRT), Clinical Status and Symptom Response Therapy (CSSRT)
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- University of Pittsburgh
Schizophrenia; Psychosis, Metabolic Syndrome
Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients
Fute (Flupentixol) combined with MARTAs (Multiple-Acting Receptor Targeted Antipsychotics) drugs has its clinical efficacy toward positive symptoms and might reduce the metabolic syndrome-related factors in patients.
- Conditions
- Schizophrenia; Psychosis, Metabolic Syndrome, Flupentixol, Antipsychotic Agents
- Trial name
- NCT04898270
- Testing
- Flupentixol, Multi-acting receptor-targeted antipsychotics (MARTAs)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Taichung Veterans General Hospital
Systemic Inflammatory Response Syndrome
INFLACOR - Clinical and Genetic Predictors of Inflammation Related Complications After Heart Surgery
The aim of the study is to evaluate a clinically and economically most effective diagnostic algorithm for prediction of inflammatory response related complications in patients undergoing heart surgery with use of cardiopulmonary…
- Trial name
- INFLACOR (NCT01020409)
- Testing
- cardiac surgery with CPB use
- Where
- Poland
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Medical University of Gdansk
Psychotic Disorders, Acceptance and Commitment Therapy
Inpatient Group Acceptance and Commitment Therapy (ACT) for Psychosis Spectrum Disorder
The pilot study that will serve as the basis for the larger project - a multicenter randomized controlled single-blinded trial (RCT) will focus on testing the feasibility and efficacy of an inpatient group ACT treatment program…
- Conditions
- Psychotic Disorders, Acceptance and Commitment Therapy, Psychotherapy, Group, Inpatients
- Trial name
- ASPIRE (NCT06086184)
- Testing
- ACT group therapy
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Vivantes Netzwerk für Gesundheit GmbH
Schizophrenia, Bipolar Disorder
Indicated Prevention of Psychotic Disorders With Low-dose Lithium
This study investigates the neuroprotective properties of low-dose lithium in young individuals at ultra-high risk of developping a first psychotic episode.
- Conditions
- Schizophrenia, Bipolar Disorder, Psychotic Disorders
- Trial name
- NCT00202306
- Testing
- lithium carbonate
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Melbourne Health
Schizophrenia, Schizoaffective Disorder
Neurophysiological Studies in Schizophrenia and Psychiatric Disorders
The overall goal of this project is to identify intermediate phenotypes for psychosis across the schizophrenia and bipolar disorders boundary with implications for future genetic studies.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- BSNIP (NCT01384604)
- Where
- United States
- Volunteers
- 1,189 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Psychotic Disorders, Schizophrenia
Mindfulness Group-based Intervention for Early Psychosis
Recent research has suggested that mindfulness-based interventions (MBI) for psychosis may be effective in reducing the negative symptoms of schizophrenia (e.g., social withdrawal, lack of motivation) and the distress associated…
- Trial name
- NCT03143907
- Testing
- Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
- Where
- 5 sites in Canada
- Volunteers
- 70 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Schizophrenia
A 20-Year Follow-up of First Episode Psychosis: Longitudinal Effects of Early Treatment Strategies and Relapse
The study aims to address the following questions: 1. Do subgroups defined by early medication choices, relapse, and medication taken over 20 years differ in clinical, cognitive, and functional outcomes? 2.
- Trial name
- NCT07616999
- Where
- China
- Volunteers
- 178 people
- Sponsor
- The University of Hong Kong
Engagement, Patient, First Episode Psychosis
Optimizing Engagement in Services for First-Episode Psychosis
This study will compare a 12-session behavioral activation (BA) intervention modified for first-episode psychosis (FEP) to usual community mental health care (i.e., treatment-as-usual; TAU) delivered over 6 months with a sample…
- Trial name
- NCT05310838
- Testing
- Behavioral Activation for First Episode Psychosis, Treatment As Usual
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- California State University, San Bernardino
Schizophrenia, Psychotic Disorder NOS
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
The primary objective of this study is to determine if NAC, added to existing antipsychotic treatment, is superior to placebo for cortical erosion in patients with early stage psychosis.
- Conditions
- Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
- Trial name
- Breier-Stanley (NCT01339858)
- Testing
- N-Acetyl Cysteine, sugar pill
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Indiana University
Schizophrenia, Schizoaffective Disorder
Development of a Mobile System for Self-management of Schizophrenia (SOS)
This 2-arm clinical trial piloted a mobile Self-Management of Schizophrenia (SOS) system that administers interventions targeting persistent symptoms of psychosis, social dysfunction, and medication adherence.
- Trial name
- NCT01969500
- Testing
- Mobile Application, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Clinical High Risk for Psychosis (CHR)
Efficacy of Mindfulness in PREventing Progression to Psychosis in Individuals With an Ultra High Risk for Psychosis
The main objective is to evaluate the efficacy of a group-based mindfulness therapy programme in reducing distress associated with symptoms of UHR (Ultra High Risk) or FEP (first psychotic episode) compared with usual treatment.
- Trial name
- EM-PREPS (NCT06870305)
- Testing
- MBTP : Mindflulness based training for psychosis
- Where
- 2 sites in France
- Volunteers
- 270 people
- Sponsor
- Centre Psychothérapique de Nancy
Paranoia, Psychotic Disorders
Racial Disparities in the Expression of Paranoia
Paranoia is a pattern of thinking in which people feel suspicious or believe others may want to harm them. It can occur in many people, not only those with a mental health diagnosis, and it can affect daily life, relationships…
- Trial name
- NCT07460453
- Testing
- Guided Visual Imagery Task
- Where
- United States
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Indiana University
Psychosis, Remission
Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States
A 2-year prospective observational study comparing a group of patients in remitted states of psychosis undergoing guided antipsychotic dose reduction to a similar group of patients under maintenance antipsychotic treatment with…
- Trial name
- GDR (NCT03248180)
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- National Taiwan University Hospital
Psychosis
Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis
The purpose of this study is to test the feasibility of a modification of CET (Cognitive Enhancement Therapy) to address symptomatic and functional difficulties associated with Clinical High Risk for Psychosis (CHR).
- Trial name
- CLUES (NCT02459210)
- Testing
- CLUES, therapy and computer games
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Beth Israel Deaconess Medical Center
Psychosis
Cognitive Remediation for First Episode of Psychosis Patients
This study aims to look at the effectiveness of a combination of cognitive remediation and social cognition training to improve cognition and functioning when compared to cognitive remediation alone.
- Trial name
- NCT01967420
- Testing
- Cognitive remediation, Social cognition training
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Manchester
Parkinson Disease Psychosis
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
A study to evaluate the safety and tolerability of SEP-363856 in subjects with Parkinson's Disease Psychosis. This study is accepting male and female participants 55 years of age and older who have been diagnosed with Parkinson's…
- Trial name
- NCT02969369
- Testing
- SEP-363856
- Where
- 24 sites in United States
- Volunteers
- 39 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.